Omnipaque 350 mg I/ ml Norge - norsk - Statens legemiddelverk

omnipaque 350 mg i/ ml

ge healthcare as - joheksol - injeksjonsvæske, oppløsning - 350 mg i/ ml

Omnipaque 140 mg I/ ml Norge - norsk - Statens legemiddelverk

omnipaque 140 mg i/ ml

ge healthcare as - joheksol - injeksjonsvæske, oppløsning - 140 mg i/ ml

Omnipaque 180 mg I/ ml Norge - norsk - Statens legemiddelverk

omnipaque 180 mg i/ ml

ge healthcare as - joheksol - injeksjonsvæske, oppløsning - 180 mg i/ ml

Omnipaque 240 mg I/ ml Norge - norsk - Statens legemiddelverk

omnipaque 240 mg i/ ml

ge healthcare as - joheksol - injeksjonsvæske, oppløsning - 240 mg i/ ml

Omnipaque 300 mg I/ ml Norge - norsk - Statens legemiddelverk

omnipaque 300 mg i/ ml

ge healthcare as - joheksol - injeksjonsvæske, oppløsning - 300 mg i/ ml

Creon 10000 Norge - norsk - Statens legemiddelverk

creon 10000

viatris as - lipase / amylase / protease - enterokapsel, hard - 10000 ie / 8000 ie / 600 ie

Creon 25000 Norge - norsk - Statens legemiddelverk

creon 25000

viatris as - lipase / amylase / protease - enterokapsel, hard - 25000 ie / 18000 ie / 1000 ie

Forsteo 20 mikrog/80 mikroliter Norge - norsk - Statens legemiddelverk

forsteo 20 mikrog/80 mikroliter

paranova as - teriparatid - injeksjonsvæske, oppløsning i ferdigfylt penn - 20 mikrog/80 mikroliter

Creon 40000 Norge - norsk - Statens legemiddelverk

creon 40000

mylan - asker - lipase / amylase / protease - enterokapsel, hard - 40000 e / 25000 e / 1600 e

Cancidas (previously Caspofungin MSD) Den europeiske union - norsk - EMA (European Medicines Agency)

cancidas (previously caspofungin msd)

merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimykotika for systemisk bruk - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.